Danish cancer antibody powerhouse Genmab plans to raise US$505m in its US IPO. The money will go towards its antibody therapeutics pipeline.
Dutch biopharma company AM-Pharma B.V. has secured €116m to bring its acute kidney injury treatment into Phase III.
Belgian biotech Galapagos NV has entered into a R&D collaboration with Gilead Sciences. The US drug maker is paying up to US$5bn for Galapagos’ pipeline and drug discovery platform.
German pharma major Boehringer Ingelheim has taken over Swiss cancer immunotherapy player AMAL Therapeutics.
French microalgae specialist Microphyt has raised €28.5m to develop its microalgae portfolio for nutrition and cosmetics.
French biotech Osivax has raised €8m to fast-track development of its lead flu vaccine candidate – and branch out to Belgium.
It is one of the largest single private funding rounds a biotech company in Europe has ever pulled off. German biotech BioNTech managed to raise US$325m (€290m) in an upsized Series B round to boost its immuno-oncology pipeline.
Biophytis has priced its IPO on Nasdaq Paris. The company aims to raise up to €10.8m to advance its lead drug candidate under development for the treatment of neuromuscular diseases.
German biotech group Evotec has once more launched a spin-off: Breakpoint Therapeutics GmbH is focusing on treating cancer patients by targeting DNA damage responses.
A new collaboration aims to the urgent fight against antimicrobial resistant bacteria. Lyon-headquartered biotech Nosopharm has teamed up with German drug discovery company Evotec SE to develop a novel antibiotics class.